Lineage Cell Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Index to consolidated financial statements
| Independent Registered Public Accounting Firm - Audit Opinion Baker Tilly US, LLP (PCAOB #23) | 114 |
|---|---|
| Financial Statements: | |
| Consolidated Balance Sheets | 116 |
| Consolidated Statements of Operations | 117 |
| Consolidated Statements of Comprehensive Loss | 118 |
| Consolidated Statements of Shareholders Equity | 119 |
| Consolidated Statements of Cash Flows | 120 |
| Notes to the Consolidated Financial Statements | 121 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.